Lixisenatide Patent Expiration
Lixisenatide is used for improving glycemic control in patients with type 2 diabetes mellitus. It was first introduced by Sanofi-Aventis Us Llc
Lixisenatide Patents
Given below is the list of patents protecting Lixisenatide, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Adlyxin | US10201663 | Assembly for a drug delivery device | Mar 10, 2034 | Sanofi-aventis Us |
Adlyxin | US9408893 | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients | Aug 27, 2032 | Sanofi-aventis Us |
Adlyxin | US9821032 | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin | May 09, 2032 | Sanofi-aventis Us |
Adlyxin | US9072836 | Drive mechanism for a drug delivery device and drug delivery device | Mar 15, 2032 | Sanofi-aventis Us |
Adlyxin | US9440029 | Drive mechanism for a drug delivery device and drug delivery device | Jan 30, 2032 | Sanofi-aventis Us |
Adlyxin | US9511193 | Assembly and indicator for a drug delivery device | Jan 19, 2032 | Sanofi-aventis Us |
Adlyxin | US9084853 | Drive mechanism for a drug delivery device and drug delivery device | Oct 05, 2031 | Sanofi-aventis Us |
Adlyxin | US8882721 | Drive assembly suitable for use in a drug delivery device and drug delivery device | Jun 28, 2031 | Sanofi-aventis Us |
Adlyxin | US8475414 | Medication delivery device and method for operating a medication delivery device | Dec 28, 2030 | Sanofi-aventis Us |
Adlyxin | US9308329 | Medication delivery device and method for operating a medication delivery device | Dec 28, 2030 | Sanofi-aventis Us |
Adlyxin | US10028910 | Pharmaceutical composition comprising a GLP-1-agonist and methionine | Nov 11, 2030 | Sanofi-aventis Us |
Adlyxin | US9707176 | Pharmaceutical composition comprising a GLP-1 agonist and methionine | Nov 11, 2030 | Sanofi-aventis Us |
Adlyxin | US9981013 | Use of AVE0010 for the treatment of diabetes mellitus type 2 | Aug 30, 2030 | Sanofi-aventis Us |
Adlyxin | US8915888 | Dosing and drive mechanism for drug delivery device | Jun 08, 2030 | Sanofi-aventis Us |
Adlyxin | US9855388 | Dosing and drive mechanism for drug delivery device | Apr 24, 2029 | Sanofi-aventis Us |
Adlyxin | USRE45313 | Exendin variant peptides |
Jul 12, 2020
(Expired) | Sanofi-aventis Us |
Lixisenatide's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List